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Bilirubin belongs to a phylogenetically old superfamily of tetrapyrrolic compounds, which
have multiple biological functions. Although for decades bilirubin was believed to be only
a waste product of the heme catabolic pathway at best, and a potentially toxic compound
at worst; recent data has convincingly demonstrated that mildly elevated serum bilirubin
levels are strongly associated with a lower prevalence of oxidative stress-mediated dis-
eases. Indeed, serum bilirubin has been consistently shown to be negatively correlated to
cardiovascular diseases (CVD), as well as to CVD-related diseases and risk factors such
as arterial hypertension, diabetes mellitus, metabolic syndrome, and obesity. In addition,
the clinical data are strongly supported by evidence arising from both in vitro and in vivo
experimental studies. This data not only shows the protective effects of bilirubin per se;
but additionally, of other products of the heme catabolic pathway such as biliverdin and
carbon monoxide, as well as its key enzymes (heme oxygenase and biliverdin reductase);
thus, further underlining the biological impacts of this pathway. In this review, detailed
information on the experimental and clinical evidence between the heme catabolic path-
way and CVD, and those related diseases such as diabetes, metabolic syndrome, and
obesity is provided. All of these pathological conditions represent an important threat to
human civilization, being the major killers in developed countries, with a steadily increasing
prevalence. Thus, it is extremely important to search for novel markers of these diseases,
as well as for novel therapeutic modalities to reverse this unfavorable situation. The heme
catabolic pathway seems to fulﬁll the criteria for both diagnostic purposes as well as for
potential therapeutical interventions.
Keywords: bilirubin, biliverdin, biliverdin reductase, cardiovascular diseases, diabetes, heme oxygenase, metabolic
syndrome, UGT1A1
INTRODUCTION
Bilirubin belongs to the superfamily of tetrapyrrolic compounds,
which is one of the most highly conserved groups of molecules
in nature. Tetrapyrroles have evolved to have pluripotent func-
tions, including light harvesting in plants; as well as other roles
in plants as well as in humans: chronobiology, energy generation,
transport, and homeostasis of oxygen by hemoglobins and myo-
globin – to mention only a few of them. Although for decades
bilirubin was believed to be a potentially toxic metabolite of heme
catabolism, in particular for central nervous system, data from the
last few decades clearly demonstrates that this tetrapyrrolic com-
pound might also have numerous other beneﬁcial effects for the
human body, including the scavenging of overproduced reactive
oxygen species, anti-inﬂammatory actions, or direct effects upon
cell signaling.
Bilirubin is the end product of heme catabolism in the sys-
temic circulation. It is formed by the action of heme oxygenase
(HMOX), an enzyme that splits cyclic tetrapyrrole heme into
biliverdin, carbon monoxide, and ferrous iron. Biliverdin is sub-
sequently reduced to bilirubin by biliverdin reductase (BLVRA).
HMOXexists in two isoforms:HMOX1,a highly inducible isoform
responsible for reactions of acute phase immediate response
against oxidative stress, and a constitutive isoenzyme HMOX2,
playing important roles in the brain and testes. The third mem-
ber of the HMOX family (HMOX3) has also been described, but
it is generally believed that HMOX3 is only represented by a
pseudogene,with no coding function (Hayashi et al., 2004).Never-
theless, in light of the recent discoveries of the possible regulating
functions of pseudogenes (Pink et al., 2011), it is possible that
HMOX3 might also have biological effects by contributing to gene
regulation.
Bilirubin, as a non-polar molecule, is solubilized in the vas-
cular bed by binding to albumin. When reaching the liver, it is
actively transported by the basolateral OATP transporter, solubi-
lized in the cytoplasm by binding to speciﬁc binding proteins,
and subsequently conjugated by the action of bilirubin UDP-
glucuronosyltransferase (UGT1A1) with two molecules of glu-
curonic acid. Bisglucuronosyl bilirubin is then actively secreted
into bile and proceeds into the intestinal lumen, where it under-
goes further metabolic changes. From the metabolic point of view,
there are several crucial enzymatic steps (in particular those cat-
alyzed by HMOX1, BLVRA, and UGT1A1 enzymes) which play an
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important role in bilirubin homeostasis with subsequent impacts
on the risk of metabolic diseases, including cardiovascular diseases
(CVD), diabetes, metabolic syndrome, arterial hypertension, and
obesity.
Serum bilirubin concentrations are affected by many factors
including cigarette smoking, gender, fasting, intake of numerous
drugs and/or plant products, altitude, race, and age (for review
see Vítek and Schwertner, 2007b). All these factors are likely to
inﬂuence biological impact of bilirubin on human body.
BIOLOGICAL PROPERTIES OF BILIRUBIN
Bilirubin has been recognized as a substance with potent antiox-
idant properties. The ﬁrst report on the antioxidant effects of
bilirubin was published as early as 1954 (Bernard et al., 1954),
however, it took severalmore decades until the antioxidant proper-
ties of bilirubin attracted major scientiﬁc attention (Stocker et al.,
1987). Indeed, bilirubin has been shown to be more effective at
protecting lipids from oxidation than the water-soluble antioxi-
dants such as glutathione, which primarily protect proteins from
oxidation (Sedlak et al., 2009). However, bilirubin has also been
demonstrated to be almost 30 times more potent toward the pre-
vention of LDL oxidation compared to a vitamin E analog, Trolox,
which represents a lipid-soluble antioxidant substance (Wu et al.,
1994). Even more importantly, serum bilirubin has been demon-
strated to be a major contributor to the total antioxidant capacity
in blood plasma (Frei et al., 1988). Additionally, bilirubin has
been proven to have anti-inﬂammatory properties (for review see
Vítek and Schwertner, 2007b). Bilirubin inhibited tumor necrosis
factor α-induced up-regulation of E-selectin, vascular cell adhe-
sion molecule-1 (VCAM-1), and intercellular adhesion molecule
(ICAM-1) in vitro (Mazzone et al., 2009). The negative association
between serum bilirubin levels and soluble forms of CD40 ligand
and P-selectin which have also been demonstrated in in vivo study
on subjects with Gilbert syndrome (Tapan et al., 2009). Bilirubin
has also been shown to signiﬁcantly interfere with the complement
system, with all of the possible protective consequences (reviewed
in Basiglio et al., 2010). Consistent with this data, several studies
have demonstrated a negative relationship between serum biliru-
bin and C-reactive protein levels (Vítek et al., 2007a; Hwang et al.,
2011; Yoshino et al., 2011). In addition, the modulatory effects of
bilirubinonT regulatory cell differentiationwere recently reported
(Rocuts et al., 2010), further underlining the protective role of
bilirubin in the pathogenesis of chronic inﬂammatory as well as
in autoimmune conditions.
NEGATIVE ASSOCIATION BETWEEN BILIRUBIN AND
CARDIOVASCULAR DISEASES
The ﬁrst report of a negative relationship between serum biliru-
bin levels and coronary artery disease was published as early
as 1994 (Schwertner et al., 1994). Since then, numerous stud-
ies have been published, which have consistently demonstrated
that subjects with lower bilirubin levels are at increased risk of
both coronary and peripheral atherosclerotic disease (for reviews
see recent papers; Vítek and Schwertner, 2007b; Schwertner and
Vítek, 2008; Vítek and Ostrow, 2009; Lin et al., 2010). Serum
bilirubin concentrations were also found to be negatively related
to coronary artery calciﬁcation (Tanaka et al., 2009), and also
to ischemic stroke (Kimm et al., 2009); all consistent with our
own data which demonstrated a marked postponement in the
progression of the intimo-medial thickness of carotid arteries in
hyperbilirubinemic subjects with Gilbert syndrome, when com-
pared to normobilirubinemic individuals (Vítek et al., 2006). In
addition, our meta-analysis of studies focused on the associa-
tion between CVD and bilirubin, involving almost 15,000 men,
showed that each 1.0μmol/L increase in serum bilirubin was asso-
ciated with a 6.5% decrease in CVD risk (Novotný and Vítek,
2003). The same association was also reported in a recent Tai-
wanese prospective study on patients with cardiac X syndrome
followed for 5 years, in which patients with the lowest serum
bilirubin levels had a higher incidence of non-fatal myocardial
infarction, ischemic stroke, rehospitalization for unstable angina,
and coronary revascularization procedures (Huang et al., 2010).
Logically, the opposite relationship is also true, i.e., subjects
with moderately elevated levels of serum bilirubin, such as those
with Gilbert syndrome, are at decreased risk of CVD (Vítek et al.,
2002).
Although the association of serum bilirubin levels and CVD
has been known for almost two decades, the relationship between
bilirubin andother players of theheme catabolic pathway,aswell as
pathologic conditions such asmetabolic syndrome and/or diabetes
has only been investigated in the last few years.
HEME OXYGENASE AND DIABETES – EXPERIMENTAL
EVIDENCE
Diabetes mellitus, the hallmark of which consists of elevated
plasma glucose, is consistently associated with increased oxida-
tive stress, as well as enhanced formations of advanced glycation
end products (AGEs; Yamagishi et al., 2011). Overproduction of
oxidizing molecules results in the progressive loss of pancreatic
β-cells, depleting insulin levels. However, also numerous other
mechanisms contributing to the pathogenesis of diabetes play an
important pathogenic role, including reduction of the adiponectin
levels (Soares et al., 2005), interference with insulin signaling,
endothelial dysfunction, or direct damages of the endothelial wall
(Unoki and Yamagishi, 2008; Potenza et al., 2009; Giacco and
Brownlee, 2010). Thus, it is not surprising that HMOX1, as a
key antioxidant enzyme, has consistently been shown to protect
from the development of diabetes (for review see Ndisang, 2010).
The mechanisms by which HMOX1 mediated these effects are
pluripotent, and apart from the antioxidant action, HMOX1 also
directly affects glucose metabolism, which might be due to the
presence of a binding site for a glucocorticoid-responsive element
in the HMOX1 gene promoter (Lavrovsky et al., 1996). In fact,
HMOX1 was shown to stimulate insulin production in experi-
mental animal models (Ndisang, 2010), at least partially, via the
release of carbon monoxide (Henningsson et al., 1999), which
is an immediate product of HMOX. Indeed, HMOX1 induction
by hemin has been demonstrated to improve insulin signaling
and glucose metabolism, and to have lowered insulin resistance in
various animal models, including those of streptozotocin-induced
diabetes (Ndisang and Jadhav, 2009a), insulin-resistant type 2 dia-
betes (Ndisang and Jadhav, 2009b), primary hyperaldosteronism
(Ndisang and Jadhav, 2010a), as well as essential hypertension
(Ndisang et al., 2010b). Apart from an improvement of insulin
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sensitivity,HMOX1 induction was also reported to reduce visceral
and subcutaneous obesity in diabetic and obese mice (Li et al.,
2008; Nicolai et al., 2009; Burgess et al., 2010) through mecha-
nisms involving the attenuation of the inﬂammatory processes, as
well as modulation of PPARγ signaling (Ndisang, 2010). Further-
more, chronicHMOX1 inductionwas shown to increasemetabolic
turnover,heat production, and physical activity in an experimental
model of obesity (Csongradi et al., 2012), suggesting the com-
plexity of the beneﬁcial effects of HMOX1 induction upon these
metabolic disorders.
HEME OXYGENASE AND DIABETES – CLINICAL EVIDENCE
Experimental data on the role of HMOX in the pathogenesis of
diabetes, metabolic syndrome, and obesity are also supported by
the clinical evidence. Plasma concentrations of HMOX1 have been
demonstrated to strongly correlate with type 2 diabetes melli-
tus (Bao et al., 2010b). In fact, subjects in the highest quartile
of HMOX1 plasma levels had more than an 8X higher risk for
development of type 2 diabetes, compared to the lowest quartile
(Bao et al., 2010b). In this study, the HMOX1 plasma level might
reﬂect increased oxidative stress preceding the expression of dia-
betes. In addition, it is known that high glucose exposure leads to
HMOX1 induction (Jonas et al., 2003;Won et al., 2006),which also
might account for the observed phenomenon. On the other hand,
the same authors recently published a meta-analysis of six stud-
ies focused on the role of HMOX1 promoter gene variants and
the risk of diabetes, covering almost 2,000 diabetic patients and
3,500 controls. These results revealed that subjects carrying longer
(GT)n repeats in the HMOX1 gene promoter (associated, never-
theless, with decreased HMOX1 activity), had an increased risk of
type 2 diabetes (Bao et al., 2010a). In addition to the effect on dia-
betes risk, diabetic subjects with the L/L genotype had an almost
threefold increase in CVD risk, even after controlling for conven-
tional risk factors in one of the studies involved in the reported
meta-analysis (Chen et al., 2008). Further detailed clinical studies
are needed to elucidate all of the mechanisms related to the roles
of HMOX in the risks of development of diabetes.
BILIVERDIN REDUCTASE AND DIABETES – EXPERIMENTAL
EVIDENCE AND POSSIBLE CLINICAL IMPLICATIONS
Biliverdin reductase, similarly as HMOX, is an evolutionarily con-
served enzyme, responsible for the hydrogenation of biliverdin
on bilirubin. Besides that, BLVRA has multiple other functions
affecting cell signaling, modulating immune system response, and
also exerting substantial metabolic effects (Maines, 2005; Kapitul-
nik and Maines, 2009; Wegiel et al., 2011). BLVRA also serves as
a unique serine/threonine/tyrosine kinase, signiﬁcantly modulat-
ing (among other molecules) the phosphorylation of the insulin
receptor substrate-1, as well as other insulin/IGF-1 signaling path-
way targets (Kapitulnik and Maines, 2009). As a result, BLVRA
diminishes insulin signaling, and acts as a negative regulator
of glucose uptake (Lerner-Marmarosh et al., 2005). BLVRA also
binds to the p85 regulatory subunit of PI3K/Akt (Pachori et al.,
2007), a mechanism which might also lead to improved insulin
sensitivity (Terauchi et al., 1999). Based upon this data, small
BLVRA-based peptides which activate the insulin receptor signal-
ing axis have been suggested as possible therapeutics to combat
insulin resistance in diabetic patients (Lerner-Marmarosh et al.,
2008).
Not only BLVRA itself, but also the products of its basic enzy-
matic activity, biliverdin (and consequently bilirubin), might sig-
niﬁcantly contribute to protection from diabetic complications.
Oral administration of biliverdin to db/db mice partially prevented
aworsening of hyperglycemia and glucose intolerance (Ikeda et al.,
2011), as well as diabetic nephropathy in these animals, princi-
pally via inhibition of oxidative stress-induced damage, mediated
by the interference with the NADPH oxidase pathway (Fujii et al.,
2010). Biliverdin-treated animals had less albuminuria, and com-
plete protection against the progression of mesangial expansion,
accompanied by normalization of transforming growth factor-β1
and the expression of ﬁbronectin (Fujii et al., 2010).
There are no clinical data on the role of BLVRA/biliverdin in
diabetes, metabolic syndrome, or obesity. Only recently, a paper
describing the effect of a BLVRA gene variant (rs699512) on the
risk of essential hypertension has just been reported (Lin et al.,
2011). Detailed studies are certainly needed to fully elucidate the
clinical relevance of the experimental ﬁndings discussed.
BILIRUBIN AND DIABETES – EXPERIMENTAL EVIDENCE
It is not surprising that bilirubin, a subsequent reduction product
of biliverdin, also has salutary effects in terms of the prevention of
diabetes mellitus and its complications. In addition, bilirubin was
also reported to provide protection against metabolic syndrome,
and to be negatively associated with overweight and obesity.
In fact, in a manner similar to biliverdin substantially improv-
ing renal pathology in db/db mice, speciﬁcally via inhibition
of NADPH oxidase (as discussed above), a practically identical
effect was observed in hyperbilirubinemic Gunn rats exposed
to streptozocin (Fujii et al., 2010). Compared to their diabetic
normobilirubinemic heterozygous siblings, diabetic Gunn rats
developed less albuminuria, exhibited practically normal urinary
levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), as well as 8-
epi-prostaglandin F2α levels; both markers of systemic oxidative
stress. Additionally, expression of NADPH oxidase was markedly
attenuated in the kidneys of diabetic Gunn rats, who also exhib-
ited complete inhibition of mesangial expansion when compared
to normobilirubinemic diabetic controls (Fujii et al., 2010). Con-
sistent with this data, Korean researchers reported substantial
resistance of hyperbilirubinemic Gunn rats to developing diabetes
after intraperitoneal exposure to streptozocin, compared to their
normobilirubinemic littermates (Fu et al., 2010). Markers of dia-
betes, such as fasting blood glucose and HbA1c levels were much
less pronounced in Gunn rats; on the other hand, insulin secretion
by the pancreatic islets was preserved in hyperbilirubinemic ani-
mals. In addition, concentrations as low as 1.7μmol/L bilirubin
prevented streptozocin-induced apoptosis in rat insulinoma cell
culture; signiﬁcantly supporting the in vivo data (Fu et al., 2010).
BILIRUBIN, DIABETES, METABOLIC SYNDROME, AND
OBESITY – CLINICAL EVIDENCE
Negative associations between serumbilirubin concentrations and
abnormal glucose tolerance tests were reported as early as 1996
(Ko et al., 1996). Since then, numerous clinical studies evaluating
the possible associations between serum/plasma bilirubin levels
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and the risk of diabetes (and its complications) have been pub-
lished. Inoguchi et al. (2007) ﬁrst indicated that diabetic patients
who have concomitant Gilbert syndrome have a lower prevalence
rate of vascular complications, compared to normobilirubinemic
diabetics. Although not speciﬁcally mentioned in their study, the
prevalence of Gilbert syndrome among more than 5,000 consecu-
tive diabetics was at least three times lower than would be expected
in the general population. This data is in line with our observa-
tion of low prevalence of diabetes in subjects with (TA)7 promoter
variation in UGT1A1 responsible for systemic bilirubin homeosta-
sis (Jirásková et al., 2011), and with low levels of AGEs in Gilbert
syndrome subjects, compared to the normobilirubinemic popu-
lation (Kalousová et al., 2005). Furthermore, low serum bilirubin
levels were identiﬁed as an important predictor of CVD in Type 2
diabetes patients receiving haemodialysis (Fukui et al., 2011). Just
recently, another group of Japanese investigators reported in their
cross-sectional study on more than 3,000 participants, that com-
pared to subjects within the lowest bilirubin quartile, those with
the highest bilirubin levels had a four times lower prevalence of
diabetic retinopathy (Yasuda et al., 2011). In a large Korean cross-
sectional studyonalmost 94,000 subjects,high serumbilirubinwas
also found to be associated with the reduced risk of diabetes mel-
litus and diabetic nephropathy (Han et al., 2010). Higher serum
bilirubin levels were also shown to protect from diabetes melli-
tus in the US National Health and Nutrition Examination Survey
(NHANES) on almost 16,000 subjects. In this study, subjects with
a bilirubin level above 10μmol/L had 20% less risk of developing
diabetes, compared to those with bilirubin levels below this cut-off
value, even after multiple adjustments (Cheriyath et al., 2010).
Similarly, additional studies have supported the protective
effects of bilirubin on both clinical and laboratory outcomes of
diabetic subjects. Serum bilirubin concentrations were demon-
strated to be negatively associated with albuminuria in patients
with type 2 diabetes (Fukui et al., 2008), HbA1c levels (being an
independent risk factor of CVD) in Japanese populations (Oda,
2010; Oda and Kawai, 2010; Ohnaka et al., 2010); additionally,
with both insulin resistance and prevalence rate of the metabolic
syndrome among children and adolescents (Lin et al., 2009a), as
well as in adult populations (Kwon et al., 2011; Wu et al., 2011).
Consistent with this data, low prevalence of metabolic syndrome
in subjects with phenotypic Gilbert syndrome was described in a
recent large Korean study on more than 12,000 participants (Choi
et al., 2011).
In line with these negative relationships between serum biliru-
bin levels and metabolic syndrome, a negative association between
bilirubin levels and abdominal obesity per se has been shown in
several recent studies (Bhuiyan et al., 2008; Lin et al., 2009a; Choi
et al., 2011; Kwon et al., 2011;Wu et al., 2011). Since weight reduc-
tion is known to reduce several cardiovascular risk factors, it is
important to note that each one percent decrease in weight loss
was associated with a linear increase in serum bilirubin concen-
tration (Andersson et al., 2009). The close relationship between
serum bilirubin levels and the UGT1A1 gene promoter variants,
responsible for manifestation of Gilbert syndrome in Asians, and
the risk of non-alcoholic fatty liver disease (a condition commonly
associated with obesity and metabolic syndrome) was recently
demonstrated in Taiwanese children (Lin et al., 2009b); further
underlining the importance of the heme catabolic pathway in the
pathogenesis of obesity, metabolic syndrome, diabetes mellitus
and its complications.
PHARMACOLOGIC AND/OR NUTRACEUTIC INTERVENTIONS
Interventions which induce HMOX1 and/or BLVRA, or those
that inhibit UGT1A1 activities might be effective in increasing
serumand tissue bilirubin concentrations, aswell as inmodulating
signaling pathways involved in energy homeostasis.
Heme oxygenase 1, as a highly inducible enzyme, which
can be upregulated by many common drugs routinely used
in clinical medicine (Bach, 2005), including non-steroidal anti-
inﬂammatory drugs, hypolipidemics (Muchová et al., 2007; Wu
et al., 2012),PPARα agonists, certain immunosuppressive drugs, to
mention just a few. It is likely that at least part of their therapeutic
action might be mediated via induction of HMOX1. The thera-
peutic potential of HMOX1 induction is also supported by recent
experimental data demonstrating that chronic HMOX1 induction
lowers body weight, corrects hyperglycemia and hyperinsuline-
mia, as well as increases oxygen consumption, heat production,
and activity in obese mice (Csongradi et al., 2012).
Based on recent data, it also becomes evident that BLVRAmight
have great therapeutic implications (Maines, 2010). In fact, small
residue peptides designed according to the primary structure of
BLVRA were shown to block important pathways implicated in the
pathogenesis of diabetes, including the inhibition of the MAPK
(Lerner-Marmarosh et al., 2008) and TNF-α/PKC ζ/NF-κB path-
ways (Lerner-Marmarosh et al., 2007), as well as the inhibition
of activation and membrane translocation of PKC-βII (Maines
et al., 2007). There are also pharmaceuticals capable of a partial
inhibition of UGT1A1, which in turn result in a mild elevation of
systemic bilirubin levels. Among the substances having UGT1A1
inhibiting activity is a uricosuric drug probenecid (McCarty,
2007), and also the antiviral drug atazanavir (Dekker et al., 2011).
In fact, atazanavir has been demonstrated to improve endothelial
function in patients with type 2 diabetes mellitus, most likely due
to its bilirubin-increasing activities (Dekker et al., 2011).
However, the heme catabolic pathwaymight also be potentiated
throughnon-pharmacologicmeans,and its salutary effects can, for
instance, be mimicked by tetrapyrollic compounds widely occur-
ring in plants and algae. There are numerous natural HMOX1
inducers originating from plants, including polyphenols, but also
compounds such as curcumin, or silymarin (Bonifaz et al., 2009).
Indeed, curcumin was reported to increase insulin secretion from
rat-isolated pancreatic islets via HMOX1 induction (Abdel Aziz
et al., 2010), as well as to improve clinical and laboratory mark-
ers of experimental diabetes (Gutierres et al., 2011; Soetikno et al.,
2011); the same effect was also demonstrated for silymarin-treated
diabetic rats (Vessal et al., 2010). Although the action of both com-
pounds is certainly multifactorial, HMOX1 induction seems to
play an important role in their anti-diabetic effects.
It is also tempting to speculate that oral supplementation
with nutraceuticals containing plant tetrapyrolles, such as phyco-
cyanobilins (Lee et al., 2008; Moura et al., 2011), or their increased
consumption in the form of natural foods (Tonstad et al., 2009)
might be used as a novel approach of the chemoprevention of
obesity, metabolic syndrome, and diabetes.
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CONCLUDING REMARKS
In this review, the experimental as well as clinical studies on
the associations between CVD, diabetes mellitus, metabolic syn-
drome, and obesity with the heme catabolic pathway have been
discussed. These studies unanimously show that low serum
bilirubin concentrations are associated with an increased risk
of these pathologic conditions; whereas, mildly elevated serum
bilirubin levels provide protection. Moreover, it is clear that
apart from the direct beneﬁcial effects of bile pigments, the
enzymes HMOX1 and BLVRA also play an important role in
the development of these metabolic diseases. Based on recent
data, it seems that there is a therapeutical potential to mod-
ulate HMOX1, BLVRA, and UGT1A1 activities, and/or mildly
increase bilirubin levels (or its analogs) in the systemic circulation
to suppress pathways leading to the development of diabetes
and its complications. Obviously, detailed studies to explore
this potential further appear warranted, and will deﬁnitely pro-
vide much needed evidence that the whole heme catabolic
pathway is also likely beneﬁcial for this group of metabolic
diseases.
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